Last reviewed · How we verify
MQX-503
At a glance
| Generic name | MQX-503 |
|---|---|
| Sponsor | MediQuest Therapeutics |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- MQX-503 Applied to the Hand Versus Nitroglycerin Ointment Applied to the Chest: A Pharmacokinetic Comparison (PHASE1)
- Study of a Topical Formulation for the Treatment and Prevention of Raynaud's Phenomenon Symptoms (PHASE3)
- A Study of a Topical Form of Nitroglycerin and Placebo in the Treatment and Prevention of Raynaud's Phenomenon (PHASE3)
- MQX-503 vs Nitroglycerin Ointment: A Pharmacokinetic Comparison in Normal Subjects (PHASE1)
- Dose Response Study of a Topical Formulation of Nitroglycerin for the Treatment of Raynaud's Phenomenon (PHASE2)
- Phase III Study of Topical Gel for Treatment and Prevention of Raynaud's Phenomenon (PHASE3)
- Phase III Study of a Topical Gel Formulation for Treatment and Prevention of Raynaud's Phenomenon (PHASE3)
- Lab Study of MQX-503 in Treatment of Raynaud's (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MQX-503 CI brief — competitive landscape report
- MQX-503 updates RSS · CI watch RSS
- MediQuest Therapeutics portfolio CI